Soleno Therapeutics Statistics
Share Statistics
Soleno Therapeutics has 43.12M shares outstanding. The number of shares has increased by 27.45% in one year.
| Shares Outstanding | 43.12M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 6.76% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 32.11M |
| Failed to Deliver (FTD) Shares | 764 |
| FTD / Avg. Volume | 0.11% |
Short Selling Information
The latest short interest is 6.17M, so 14.31% of the outstanding shares have been sold short.
| Short Interest | 6.17M |
| Short % of Shares Out | 14.31% |
| Short % of Float | 19.96% |
| Short Ratio (days to cover) | 8.05 |
Valuation Ratios
The PE ratio is -17.03 and the forward PE ratio is -25.49.
| PE Ratio | -17.03 |
| Forward PE | -25.49 |
| PS Ratio | 0 |
| Forward PS | 53.5 |
| PB Ratio | 4.21 |
| P/FCF Ratio | -26.62 |
| PEG Ratio | n/a |
Enterprise Valuation
Soleno Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 14.89, with a Debt / Equity ratio of 0.
| Current Ratio | 14.89 |
| Quick Ratio | 14.89 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.17 |
| Cash Flow / Debt | -91.36 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.25% and return on capital (ROIC) is -26.21%.
| Return on Equity (ROE) | -0.25% |
| Return on Assets (ROA) | -0.22% |
| Return on Capital (ROIC) | -26.21% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.18M |
| Employee Count | 33 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 22.96% in the last 52 weeks. The beta is -1.44, so Soleno Therapeutics 's price volatility has been lower than the market average.
| Beta | -1.44 |
| 52-Week Price Change | 22.96% |
| 50-Day Moving Average | 53.34 |
| 200-Day Moving Average | 47.15 |
| Relative Strength Index (RSI) | 31.55 |
| Average Volume (20 Days) | 668.45K |
Income Statement
In the last 12 months, Soleno Therapeutics had revenue of $0 and earned -$38.99M in profits. Earnings per share was $-2.36.
| Revenue | 0 |
| Gross Profit | -1.96M |
| Operating Income | -41.38M |
| Net Income | -38.99M |
| EBITDA | -37.03M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.36 |
Balance Sheet
The company has $169.68M in cash and $403.00K in debt, giving a net cash position of $169.28M.
| Cash & Cash Equivalents | 169.68M |
| Total Debt | 403.00K |
| Net Cash | 169.28M |
| Retained Earnings | -276.41M |
| Total Assets | 296.71M |
| Working Capital | 243.24M |
Cash Flow
In the last 12 months, operating cash flow was -$24.94M and capital expenditures $0, giving a free cash flow of -$24.94M.
| Operating Cash Flow | -24.94M |
| Capital Expenditures | 0 |
| Free Cash Flow | -24.94M |
| FCF Per Share | -1.51 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
SLNO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.07% |
| FCF Yield | -1.24% |
Analyst Forecast
The average price target for SLNO is $72, which is 54.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $72 |
| Price Target Difference | 54.5% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Aug 26, 2022. It was a backward split with a ratio of 1:15.
| Last Split Date | Aug 26, 2022 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | 34.99 |
| Piotroski F-Score | 3 |